Clinical Trial Update: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigating IGF-1 treatment for short stature due to PAPP-A2 deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Stature

Drugs mentioned

• IGF-1 treatment (insulin-like growth factor 1)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Short Stature | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-28